SEHK:2096Pharmaceuticals
A Look At Simcere Pharmaceutical Group (SEHK:2096) Valuation As 2025 Growth Guidance Draws Investor Focus
Guidance-driven spotlight on Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (SEHK:2096) has issued consolidated guidance for 2025, indicating expected revenue of RMB 7,700 million to RMB 7,800 million and profit attributable to equity shareholders of RMB 1,300 million to RMB 1,400 million.
See our latest analysis for Simcere Pharmaceutical Group.
The guidance update comes after a mixed share price run, with a 7 day share price return of 3.55% and a 90 day share price return decline...